Evidence map›Paper›PMID 23292345›Full record

ArticleThe Journal of antimicrobial chemotherapy2013

A member of the Ras oncogene family, RAP1A, mediates antileishmanial activity of monastrol.

Jaspreet Kaur, Sujoy Dutta, Kwang-Poo Chang, Neeloo Singh

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Jaspreet KaurDrug Target Discovery & Development Division, Central Drug Research Institute (CSIR), Chattar Manzil Palace, Lucknow, India.
Sujoy Dutta
Kwang-Poo Chang
Neeloo Singh
Central Drug Research Institute · INRosalind Franklin University of Medicine and Science · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the mode of action of monastrol in intracellular Leishmania.

methodsMicroarray experiments were conducted on an Affymetrix GeneChip(®) Human Genome U133 Plus 2.0 Array, to determine the genes that encode proteins related to pathological alterations of cell signalling pathways in intracellular Leishmania amastigotes in response to monastrol treatment.

resultsMonastrol induced unprenylated Rap1A in intracellular Leishmania when exposed to this anticancer drug at the IC50 (10 μM). Monastrol, known to cause mitotic arrest in cancer cells, inhibited Rap1A prenylation (geranylgeranylation) in intracellular Leishmania, which resulted in blockade at the G1 phase of the cell cycle. Growth inhibition, rather than apoptosis, was found to be the mechanism by which monastrol displays antileishmanial activity.

conclusionsPrenylation inhibitors (unprenylation) of cell signalling pathways can be exploited in Leishmania parasites as novel therapeutic tools.

Indexed as

Antiprotozoal AgentsCell Cycle CheckpointsGene Expression ProfilingHumansLeishmaniaMicroarray AnalysisPrenylationProtein Processing, Post-TranslationalPyrimidinesrap1 GTP-Binding ProteinsThionesAntiprotozoal AgentsmonastrolPyrimidinesRAP1A protein, humanrap1 GTP-Binding ProteinsThiones

Identifiers

PMID23292345
PMCPMC3625431
OpenAlexW2131301278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.